The Gut-Brain Axis: IBS as Comorbidity and Comparator

TipAchievement: IBS: The Strongest Genetic Correlation

IBS shares the strongest genetic correlation with ME/CFS of any condition: rg=0.75 β€” stronger than fibromyalgia, stronger than autoimmune disease, stronger than any psychiatric condition. The temporal relationship is informative: IBS typically develops after ME/CFS onset, and its prevalence (50–60% in ME/CFS cohorts) is most plausibly explained as secondary autonomic GI dysfunction and gut barrier impairment rather than as an independent comorbid disease.

Three competing mechanistic models for the shared heritability: (1) glutamatergic (shared synaptic dysfunction affecting both CNS and enteric nervous system), (2) serotonergic (shared 5-HT dysregulation β€” 95% of serotonin is gut-derived, enterochromaffin cells express the same genetic program in both conditions), and (3) autonomic (shared sympathetic-parasympathetic imbalance affecting both cardiovascular and GI function). Local genetic correlation analysis can discriminate these.

Consequence: The genetic data strongly support lumping IBS with ME/CFS and fibromyalgia into a shared genetic architecture. The temporal sequence (ME/CFS β†’ IBS) supports interpreting IBS as a downstream consequence β€” shared genes establish susceptibility, and ME/CFS-triggered autonomic dysfunction activates the enteric manifestation. This has clinical implications: treating ME/CFS autonomic dysfunction may improve IBS symptoms without IBS-specific interventions.

Severity applicability: Unknown β€” GI symptom studies rarely stratify by ME/CFS severity.

CautionSpeculation: Gut-Peripheral Serotonin Dysregulation as Shared Mechanism

(Certainty: 0.40.) Anti-5-HT autoantibodies linked to LPS/IgA (markers of gut permeability) have been reported in both ME/CFS and IBS, suggesting shared enterochromaffin cell dysfunction. If gut barrier impairment (documented in ME/CFS β€” elevated LBP, reduced SCFA-producing bacteria) allows luminal serotonin to contact the immune system, anti-serotonin autoantibody production could produce systemic serotonin depletion, explaining both GI symptoms (local) and cognitive/mood symptoms (central via reduced serotonin availability).

The nosological implication: ME/CFS and IBS may not be two independent conditions with high comorbidity but rather two organ-level manifestations of the same systemic process β€” immune activation β†’ gut barrier breakdown β†’ anti-serotonin autoantibodies β†’ serotonin depletion β€” with the predominant symptom location (GI vs CNS vs both) determined by individual susceptibility factors.

Falsifiable prediction: Serum anti-5-HT autoantibody titers will correlate with both ME/CFS severity and IBS symptom scores, with intestinal permeability markers (LBP, zonulin) partially mediating the relationship. Falsified if anti-5-HT autoantibodies are specific to either ME/CFS or IBS but not both, or if they do not correlate with permeability markers.

Consequence: If validated, the gut-brain serotonin axis would collapse the IBS/ME/CFS boundary β€” the same systemic process produces both gut and brain symptoms, and the distinction between β€œa GI disease with fatigue” and β€œa neurological disease with GI symptoms” is a false dichotomy.